Cabaletta Bio (CABA) Non-Current Assets (2018 - 2025)
Cabaletta Bio's quarterly Non-Current Assets came in at $26.2 million in Q4 2025, up 42.68% year-on-year from $18.4 million in Q4 2024, and up 4.02% quarter-over-quarter from $25.2 million in Q3 2025.
Cabaletta Bio has reported Non-Current Assets for 8 years, with the latest figure at $26.2 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 42.68% year-over-year to $26.2 million; the trailing twelve-month figure through Dec 2025 stood at $108.0 million (up 75.96% YoY), and the FY2025 full-year result was $26.2 million, up 42.68% from the prior year.
- Non-Current Assets for Q4 2025 stood at $26.2 million, up from $25.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $30.5 million in Q1 2025, with the low at $1.5 million in Q1 2021.
- Average Non-Current Assets over 5 years is $11.2 million, with a median of $7.9 million recorded in 2022.
- Year-over-year, Non-Current Assets plunged 56.74% in 2021 and surged 353.15% in 2022.
- Tracing CABA's Non-Current Assets over 5 years: stood at $1.8 million in 2021, then surged by 353.15% to $8.1 million in 2022, then gained by 12.61% to $9.2 million in 2023, then surged by 100.56% to $18.4 million in 2024, then surged by 42.68% to $26.2 million in 2025.
- The last three Non-Current Assets figures came in at $26.2 million (Q4 2025), $25.2 million (Q3 2025), and $26.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 26.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.21 Mn |
| Sep 30, 2025 | 25.20 Mn |
| Jun 30, 2025 | 26.09 Mn |
| Mar 31, 2025 | 30.55 Mn |
| Dec 31, 2024 | 18.37 Mn |
| Sep 30, 2024 | 18.90 Mn |
| Jun 30, 2024 | 11.16 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Dec 31, 2023 | 9.16 Mn |
| Sep 30, 2023 | 7.11 Mn |
| Jun 30, 2023 | 7.07 Mn |
| Mar 31, 2023 | 7.71 Mn |
| Dec 31, 2022 | 8.13 Mn |
| Sep 30, 2022 | 3.50 Mn |
| Jun 30, 2022 | 3.27 Mn |
| Mar 31, 2022 | 2.22 Mn |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | 1.79 Mn |
| Jun 30, 2021 | 1.92 Mn |
| Mar 31, 2021 | 1.53 Mn |
| Dec 31, 2020 | 1.19 Mn |
| Sep 30, 2020 | 2.55 Mn |
| Jun 30, 2020 | 4.43 Mn |
| Mar 31, 2020 | 843,000.00 |
| Dec 31, 2019 | 916,000.00 |
| Sep 30, 2019 | 3.19 Mn |
| Dec 31, 2018 | 180,000.00 |